Search results | daiichi sankyo


Partnering Agreements with Daiichi Sankyo

This report provides all the information you require to better understand Daiichi Sankyo and its partnering interests and activities over the past seven years.


Daiichi Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan

Daiichi Sankyo partnering: Partnering on promising products

Daiichi Sankyo is a global pharmaceutical company engaged in the research and development, manufacturing, and sale and marketing of innovative and generic drugs, vaccines, and over-the counter medicines

Daiichi Sankyo: Partnering activity 2005-2013

Daiichi Sankyo has announced over 45 partnering / licensing deals since 2005, with 5 deals in 2012 alone

Daiichi Sankyo: M&A activity 2005-2013

Daiichi Sankyo has announced only 6 M&A deals since 2005

Daiichi Sankyo: Company Profile

Return to top 50 pharma list Summary Website: Daiichi Headquarters: Tokyo, Japan Ticker:  D4S (Frankfurt Stock Exchange) SEC: Daiichi Sankyo Recent deal news: Daiichi Sankyo deal news at Current Partnering Must read report: Partnering Deals and Alliances with Daiichi Sankyo Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. Daiichi Sankyo Co. Ltd. was more »

Daiichi Sankyo acquires Plexxikon in a $935 million deal

Hot on the heals of Plexxikon announcing positive interim data from a Phase III trial evaluating its lead oncology candidate, PLX4032

Current Agreements Deal Analysis Update : September 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in August 2014.

Life Science M&A Deal Trends in Q2, 2014

By Steve Poile                                     With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.

Industry analysis: Cancer monoclonal antibody partnering on the rise

Monoclonal antibodies are developed to be very selective in targeting cells. This is why they have come to be an indispensable research tool in cancer treatment being able to specifically target tumor cells.

A review of the Top 50 Pharma companies of 2014

The 2014 top 50 Pharma company list is out, with an interesting number of movers and shakers By Alamelu Elango


Sorry, your search returned no results.


Daiichi Sankyo announces company acquisition of Ambit Biosciences

Daiichi Sankyo and Ambit Biosciences announced the company acquisition of the Ambit in a deal valued up to $410 million.

Daiichi Sankyo to license ARQ 092 from ArQule

ArQule and Daiichi Sankyo have announced the execution of a license agreement for the development of a new AKT inhibitor called ARQ 092, the first compound to emerge from the companies’ November 2008 agreement to collaborate on research utilizing the AKIP (ArQule Kinase Inhibitor Platform) technology to generate novel, selective and potent small molecule kinase more »

CMC Biologics announces agreement with Daiichi Sankyo to develop and manufacture antibodies

Agreement with Daiichi Sankyo to provide process development support and manufacture of several clinical-stage antibodies over a three-year period. 

Pfizer and Daiichi Sankyo team up in China

Pfizer has agreed to promote a hypertension drug from Daiichi Sankyo Pharma in China. 

Daiichi Sankyo to acquire Plexxikon for $805m upfront and up to $130m in milestones

Plexxikon Inc. has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company.

KINAXO Biotechnologies and Daiichi Sankyo Sign Collaboration Agreement

Long-term partnership in cancer research. Under the agreement, Daiichi Sankyo will employ KINAXO’s technology platform to support the development of Daiichi Sankyo’s targeted cancer drugs.

Accumetrics, Daiichi Sankyo and Eli Lilly launch strategic U.S. collaboration

Accumetrics, Inc., Daiichi Sankyo, Inc, and Eli Lilly and Company announced today that the companies have entered into a strategic collaboration in the United States to raise awareness about antiplatelet therapy and the role of platelet function testing.

Daiichi Sankyo to launch products in Mexico through Ranbaxy Laboratories

Additionally, the companies have agreed to promote prasugrel, an anti-platelet co-developed by Daiichi Sankyo and Eli Lilly and Company, in Mexico. Prasugrel will be co-promoted by Lilly’s affiliate in Mexico.

BioInvent signs licensing agreement with Daiichi Sankyo for discovery and development of therapeutic antibodies

Daiichi Sankyo will be granted broad access to BioInvent’s discovery and development technology platform and in house antibody expertise. As part of the agreement, BioInvent has secured certain co-promotion rights in Scandinavia and the Baltic countries.

MorphoSys and Daiichi Sankyo forge alliance to develop novel antibody therapies against hospital-acquired infections

MorphoSys and Daiichi Sankyo will collaboratively apply HuCAL PLATINUM, the latest and most powerful version of MorphoSys’s antibody libraries.